Yes, we will be monitoring it, one reason to updat

Yes, we will be monitoring it, one reason to update today posted as a baseline.

Couple items of note:
-10Q should be out next week.
-Burn rate should reduce significantly with BLA submission. Then as the mono investigatory trial finishes, it should drop it more, unless of course they start the mono pivotal trial, which I get the feeling they will not start enrolling heavy unless the funding is secured beforehand. The mono investigatory trial was a huge burden, but was a necessity because they needed data for the BLA; so they had to push ahead without knowing where the funding would come from. We should know even more with the 10Q in April, but the R&D of 42M in 2019 and 38M in 2018 could be greatly reduced if needed in 2020. Remember the current mono investigatory trial has enrolled over 500 patients most of those the last two years. These p2 trials with cancer, nash, ms, gvhd, all combined will not even be half that number (expect for PrEP). And it looks like they will not start many of these without the funding or partnerships secured before (especially PrEP, the most taxing one).